Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595558 | 1.00 | MMP9 (0.53) | MMP9MMP8MMP14CTSLCTSB | |
| SCHEMBL24414112 | 1.00 | MMP9 (0.53) | MMP9MMP8MMP14CTSLCTSB | |
| SCHEMBL20630587 | 0.91 | CTSL (0.48) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL8355963 | 0.90 | CTSL (0.47) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL13323329 | 0.90 | CTSL (0.47) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL29670143 | 0.88 | MDM4 (0.48) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL6019560 | 0.88 | CTSL (0.56) | CTSLCTSBCTSSCTSK | |
| SCHEMBL21925581 | 0.87 | MDM4 (0.47) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL29480451 | 0.87 | CTSL (0.45) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL25178745 | 0.87 | CASP3 (0.58) | MDM4TP53CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4509517-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-07 | — | — | US | disclosed |
| WO-2023214577-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| EP-4242219-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, DNPEP, NPPA | MMP9 4287/4885MMP8 4359/4885MMP14 1966/4885 |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | MMP9 4146/4885MMP8 4390/4885MMP14 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.